Eli Lilly and Company (NYSE:LLY) Given New $1,650.00 Price Target at JPMorgan Chase & Co.

Eli Lilly and Company (NYSE:LLY) had its target price boosted by analysts at JPMorgan Chase & Co. from $1,500.00 to $1,650.00 in a research report issued to clients and investors on Friday, Benzinga reports. The firm currently has an “overweight” rating on the stock. JPMorgan Chase & Co.‘s target price would indicate a potential upside of 16.56% from the stock’s previous close.

LLY has been the subject of a number of other research reports. Argus boosted their price objective on shares of Eli Lilly and Company from $1,300.00 to $1,550.00 and gave the company a “buy” rating in a report on Friday. Sanford C. Bernstein restated an “outperform” rating and issued a $1,450.00 target price on shares of Eli Lilly and Company in a research report on Monday. Wells Fargo & Company raised their price objective on shares of Eli Lilly and Company from $1,330.00 to $1,500.00 and gave the stock an “overweight” rating in a research report on Friday. UBS Group reaffirmed a “buy” rating and set a $1,625.00 target price on shares of Eli Lilly and Company in a research report on Friday. Finally, The Goldman Sachs Group restated a “buy” rating and set a $1,413.00 price target on shares of Eli Lilly and Company in a research note on Tuesday, October 20th. One equities research analyst has rated the stock with a Strong Buy rating, twenty-four have assigned a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $1,398.43.

Eli Lilly and Company Stock Performance

LLY stock traded up $41.94 during midday trading on Friday, reaching $1,415.64. The company had a trading volume of 5,246,333 shares, compared to its average volume of 2,944,370. The firm has a market capitalization of $1.33 trillion, a PE ratio of 47.50, a P/E/G ratio of 1.73 and a beta of 0.46. The company has a quick ratio of 1.00, a current ratio of 1.35 and a debt-to-equity ratio of 1.41. Eli Lilly and Company has a fifty-two week low of $834.19 and a fifty-two week high of $1,449.68. The stock has a 50 day moving average price of $1,194.34 and a 200 day moving average price of $1,090.89.

Eli Lilly and Company (NYSE:LLY) last issued its quarterly earnings results on Thursday, October 29th. The company reported $7.48 earnings per share for the quarter, topping analysts’ consensus estimates of $5.68 by $1.80. The firm had revenue of $24.40 billion for the quarter, compared to analysts’ expectations of $22.58 billion. Eli Lilly and Company had a return on equity of 97.83% and a net margin of 33.53%. Eli Lilly and Company’s revenue was up 38.6% on a year-over-year basis. During the same quarter last year, the business posted $7.02 EPS. Analysts anticipate that Eli Lilly and Company will post 33.22 earnings per share for the current year.

Insider Transactions at Eli Lilly and Company

In related news, EVP Anat Hakim sold 5,000 shares of Eli Lilly and Company stock in a transaction dated Friday, August 7th. The stock was sold at an average price of $1,190.00, for a total value of $5,950,000.00. Following the completion of the sale, the executive vice president directly owned 11,875 shares in the company, valued at $14,131,250. The trade was a 29.63% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CAO Donald Zakrowski sold 2,000 shares of the business’s stock in a transaction on Monday, August 10th. The shares were sold at an average price of $1,185.01, for a total transaction of $2,370,020.00. Following the transaction, the chief accounting officer owned 1,526 shares of the company’s stock, valued at $1,808,325.26. This represents a 56.72% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders sold 13,500 shares of company stock worth $15,958,170. 0.14% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Several large investors have recently modified their holdings of LLY. Torren Management LLC increased its position in shares of Eli Lilly and Company by 357.1% in the 3rd quarter. Torren Management LLC now owns 32 shares of the company’s stock worth $37,000 after purchasing an additional 25 shares during the last quarter. Marshall & Sterling Wealth Advisors Inc. boosted its holdings in shares of Eli Lilly and Company by 60.0% during the 1st quarter. Marshall & Sterling Wealth Advisors Inc. now owns 40 shares of the company’s stock worth $37,000 after buying an additional 15 shares during the period. Foresight Capital Management Advisors Inc. bought a new stake in shares of Eli Lilly and Company in the 3rd quarter worth approximately $49,000. AlphaCentric Advisors LLC bought a new stake in shares of Eli Lilly and Company in the 1st quarter worth about $42,000. Finally, Caitlin John LLC acquired a new position in Eli Lilly and Company during the 2nd quarter worth about $64,000. 82.53% of the stock is currently owned by hedge funds and other institutional investors.

Trending Headlines about Eli Lilly and Company

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Q3 results substantially beat expectations. Revenue rose 39% year over year to $24.4 billion, while adjusted EPS was $7.48 versus the $5.68 consensus estimate. Mounjaro sales increased 65% to $10.7 billion and Zepbound sales rose 49% to $5.35 billion. Lilly third-quarter results
• Positive Sentiment: Lilly raised its 2026 revenue forecast to $91 billion-$92 billion, up from $85 billion-$87 billion previously. Strong demand, broader Medicare access and growing middle-income adoption are supporting expectations for continued GLP-1 expansion. Q3 earnings call highlights
• Positive Sentiment: Analysts raised their price targets and maintained bullish ratings. Scotiabank lifted its target to $1,605 with a “sector outperform” rating, Morgan Stanley raised its target to $1,596 with an “overweight” rating, and RBC moved to $1,600 with an “outperform” rating. Analyst commentary
• Positive Sentiment: Pipeline and portfolio diversification offer additional upside. Positive Phase 3 retatrutide data strengthened Lilly’s competitive position against Novo Nordisk, while oncology, immunology and neuroscience products are beginning to contribute more meaningfully. Lilly growth opportunities
• Negative Sentiment: Investors face execution and valuation risks. Realized prices fell 15%, meaning volume growth must continue to offset pricing pressure. Results also benefited from roughly $900 million in one-time items, and acquired in-process research charges weighed on earnings. With GLP-1 drugs representing a large share of revenue and the stock near its high, expectations are elevated. Reuters earnings report

Eli Lilly and Company Company Profile

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company that discovers, develops, manufactures and markets medicines for a range of medical conditions. Its major therapeutic areas include diabetes and obesity, oncology, immunology, neuroscience and cardiovascular health.

The company’s portfolio includes Mounjaro and Trulicity for diabetes, Zepbound for chronic weight management, Humalog insulin, Taltz for inflammatory diseases, Verzenio for certain breast cancers and Kisunla for early symptomatic Alzheimer’s disease.